Shurell Elizabeth, Singh Arun S, Crompton Joseph G, Jensen Sarah, Li Yunfeng, Dry Sarah, Nelson Scott, Chmielowski Bartosz, Bernthal Nicholas, Federman Noah, Tumeh Paul, Eilber Fritz C
Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, CA 90095, USA.
Department of Hematology/Oncology, University of California, Los Angeles, CA 90095, USA.
Oncotarget. 2016 Sep 27;7(39):64300-64308. doi: 10.18632/oncotarget.11734.
Malignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma with few treatment options. Tumor immune state has not been characterized in MPNST, and is important in determining response to immune checkpoint blockade. Our aim was to evaluate the expression of programmed death-ligand 1 (PD-L1), programmed cell death protein 1 (PD-1), and presence of CD8+ tumor infiltrating lymphocytes (TILs) in MPNST, and correlate these findings with clinical behavior and outcome.
PD-L1 staining of at least 1% was seen in 0/20 nerves, 2/68 benign lesions and 9/53 MPNST. Two of 68 benign lesions and 7/53 (13%) MPNST had at least 5% PD-L1 staining. CD8 staining of at least 5% was seen in 1/20 (5%) nerves, 45/68 (66%) benign lesions and 30/53 (57%) MPNST. PD-L1 was statistically more prevalent in MPNST than both nerves and benign lesions (p=0.049 and p=0.008, respectively). Expression of PD-1 was absent in all tissue specimens. There was no correlation of PD-L1 or CD8 expression with disease state (primary versus metastatic) or patient survival.
A comprehensive PNST tissue microarray was created from 141 surgical specimens including primary, recurrent, and metastatic MPNST (n=53), neurofibromas (n=57), schwannoma (n=11), and normal nerve (n=20). Cores were stained in triplicate for PD-L1, PD-1, and CD8, and expression compared between tumor types. These data were then examined for survival correlates in 35 patients with primary MPNST.
MPNST is characterized by low PD-L1 and absent PD-1 expression with significant CD8+ TIL presence. MPNST immune microenvironment does not correlate with patient outcome.
恶性外周神经鞘瘤(MPNST)是一种侵袭性肉瘤,治疗选择有限。MPNST的肿瘤免疫状态尚未明确,而这对于确定免疫检查点阻断的反应很重要。我们的目的是评估MPNST中程序性死亡配体1(PD-L1)、程序性细胞死亡蛋白1(PD-1)的表达以及CD8+肿瘤浸润淋巴细胞(TILs)的存在情况,并将这些结果与临床行为和预后相关联。
在20条神经中的0条、68个良性病变中的2个以及53个MPNST中的9个中观察到至少1%的PD-L1染色。68个良性病变中的2个以及53个(13%)MPNST中有至少5%的PD-L1染色。在20条神经中的1条(5%)、68个良性病变中的45个(66%)以及53个MPNST中的30个(57%)中观察到至少5%的CD8染色。MPNST中PD-L1在统计学上比神经和良性病变更普遍(分别为p=0.049和p=0.008)。所有组织标本中均未检测到PD-1的表达。PD-L1或CD8的表达与疾病状态(原发性与转移性)或患者生存率无相关性。
从141个手术标本创建了一个综合的PNST组织微阵列,包括原发性、复发性和转移性MPNST(n=53)、神经纤维瘤(n=57)、神经鞘瘤(n=11)和正常神经(n=20)。对核心进行一式三份的PD-L1、PD-1和CD8染色,并比较不同肿瘤类型之间的表达。然后在35例原发性MPNST患者中检查这些数据与生存的相关性。
MPNST的特征是PD-L1表达低、PD-1表达缺失且存在显著的CD8+TIL。MPNST免疫微环境与患者预后无关。